Printer Friendly

Liver carcinoma metastasis. (Clinical Capsules).

A new model and a diagnostic marker protein may help to classify hepatocellular carcinoma patients with intrahepatic metastasis, reported Qing-Hai Ye of Fudan University, Shanghai, China, and his associates.

Using 67 primary and metastatic hepatocellular carcinoma (HCC) samples from 40 patients, the researchers identified 153 genes with weights that could be used to predict the status of HCCs. The 153-gene model correctly predicted 23 (82%) of 28 patients with metastatic potential and 8 (67%) of 12 metastasis-free patients. "The prediction outcome seemed to correlate with patient survival," the researchers said, but the predictor is "only suggestive" and "has not been entirely validated and awaits confirmation from larger independent data sets" (Nat. Med. Advance Online Publication, March 17, 2003).

Among the genes the researchers identified, the osteopontin gene had a threefold higher expression of its product, SPP1, in tumor thrombi in the portal vein than in metastasis-free HCC. SPP1 is an ideal diagnostic marker because it is found in all body fluids and at an elevated level in patients with malignant tumors. SPP1 functions outside of the cell, so it is a potential target for therapy, they said.
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:new model, diagnostic marker protein for classifying hepatocellular carcinoma patients with intrahepatic metastasis
Author:Evans, Jeff
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:9CHIN
Date:Apr 15, 2003
Previous Article:Hepatocellular carcinoma risk. (Clinical Capsules).
Next Article:Infliximab immunogenicity. (Clinical Capsules).

Related Articles
Bone Metastases From Thyroid Carcinoma.
Vascular Invasion by Hepatocellular Carcinoma.
RFA may increase survival in hepatocellular carcinoma cases.
Polymorphous low-grade adenocarcinoma of the parotid gland.
Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer.
Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.
Relationship of p16 methylation status and serum [alpha]-fetoprotein concentration in hepatocellular carcinoma patients.
Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters